Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

2.

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF.

Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.

3.

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.

Jueliger S, Lyons J, Cannito S, Pata I, Pata P, Shkolnaya M, Lo Re O, Peyrou M, Villarroya F, Pazienza V, Rappa F, Cappello F, Azab M, Taverna P, Vinciguerra M.

Epigenetics. 2016 Oct 2;11(10):709-720. doi: 10.1080/15592294.2016.1214781. Epub 2016 Sep 20.

4.

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, Boehler M, Calvo Tardón M, Jueliger S, Taverna P, Barba L, Marinari E, Pellegatta S, Bassoy EY, Martinvalet D, Dietrich PY, Walker PR.

PLoS One. 2016 Aug 31;11(8):e0162105. doi: 10.1371/journal.pone.0162105. eCollection 2016.

Supplemental Content

Loading ...
Support Center